Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A045INV3 (A0A045INV3_MYCTX) Mycobacterium tuberculosis

Beta-lactamase UniProtKBInterProInteractive Modelling

307 aa; Sequence (Fasta) ; 15 identical sequences

Available Structures

69 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Beta-Lactamase, 100ms timepoint, mixed, shards crystal formhomo-4-mer43-307
PO4;9F2;FZS;
Assess
Beta-Lactamase, 500ms timepoint, mixed, shards crystal formhomo-4-mer43-307
PO4;9F2;CUG;FZS;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystalshomo-4-mer43-307
PO4;
Assess
Beta-Lactamase, 2secs timepoint, mixed, shards crystal formhomo-4-mer43-307
PO4;9F2;FZS;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;TSL;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;
Assess
XFEL structure of beta lactamase microcrystals mixed with sulbactam solution for 15mshomo-4-mer43-307
PO4;TSL;
Assess
Cryo structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;TSL;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;0RN;TSL;
Assess
XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for …homo-4-mer43-307
PO4;TSL;
Assess
Structure of G132N BlaC from Mycobacterium tuberculosismonomer41-307
GOL; 16×EDO;PO4;NA;
Assess
Crystal Structure of beta-lactamase from M.tuberculosis forming Michaelis Menten with Tebipenemmonomer42-307
PO4;1TE;
Assess
X-ray structure of the full-length beta-lactamase from M.tuberculosismonomer42-307
SO4;
Assess
Crystal Structure of BlaC-K73A bound with Cefamandolemonomer43-307
PO4;SMX;
Assess
Crystal Structure of the Ertapenem Pre-isomerized Covalent Adduct with TB B-lactamasemonomer43-307
PO4;1RG;
Assess
Structure of P226G BlaC from Mycobacterium tuberculosismonomer43-307
GOL;EDO;PO4;
Assess
Structure of G132S BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of sulbac…monomer43-307
TSL;GOL;ACT;
Assess
Crystal Structure of BlaC-E166A covalently bound with Ampicillinmonomer43-307
PO4;AIX;
Assess
Structure of D172N BlaC from Mycobacterium tuberculosismonomer43-307
EDO;
Assess
Crystal structure of A55E mutant of BlaC from Mycobacterium tuberculosismonomer43-307
GOL;PO4;
Assess
Structure of G132S BlaC from Mycobacterium tuberculosismonomer43-307
TRS;GOL;SO4;
Assess
Crystal Structure of BlaC-E166A covalently bound with Carbenicillinmonomer43-307
PO4;CB9;
Assess
Structure of E37A BlaC from Mycobacterium tuberculosismonomer43-307
Assess
Crystal Structure of BlaC-E166A covalently bound with Mecillinammonomer43-307
PO4;DH4;
Assess
Phosphoserine BlaC, Class A serine beta-lactamase from Mycobacterium tuberculosismonomer43-307
PO4;
Assess
Structure of S70C BlaC from Mycobacterium tuberculosismonomer43-307
EDO;PG0;
Assess
Crystal Structure of BlaC-E166A covalently bound with Amoxicillinmonomer43-307
AXL;PO4;
Assess
Crystal Structure of the Covalent Adduct Formed between TB B-lactamase and Clavulanatemonomer43-307
PO4;ISS;
Assess
Crystal Structure of BlaC-E166A covalently bound with Cephalotinmonomer43-307
PO4;9EP;
Assess
Crystal structure of the Mycobacterium tuberculosis beta-lactamasemonomer43-307
Assess
Structure of D179N BlaC from Mycobacterium tuberculosismonomer43-307
Assess
Meropenem Covalent Adduct with TB Beta-lactamasemonomer43-307
PO4;DWZ;
Assess
Beta-Lactamase, unmixed needles crystal formmonomer43-307
Assess
Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 100msmonomer43-307
FZS;9F2;
Assess
Structure of P167S BlaC from Mycobacterium tuberculosis at pH 6.3monomer43-307
GOL;FLC;
Assess
Structure of M.Tuberculosis Betalactamase (Blac) with inhibitor having novel mechanismmonomer43-307
33V;PO4;
Assess
Structure of D179N BlaC from Mycobacterium tuberculosis in complex with vaborbactammonomer43-307
4D6;GOL;PO4;NA;
Assess
Crystal Structure of BlaC-E166A covalently bound with Methicillinmonomer43-307
PO4;7EP;
Assess
Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 30msmonomer43-307
9F2;
Assess
Structure of P167S BlaC from Mycobacterium tuberculosis at pH 5monomer43-307
GOL;
Assess
Crystal Structure of beta-lactamase from M.tuberculosis covalently complexed with Tebipenemmonomer43-307
TEB;PO4;
Assess
Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 500msmonomer43-307
FZS;9F2;
Assess
Structure of D179N BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of sulbac…monomer43-307
TSL;GOL;PO4;
Assess
Structure of BlaC from Mycobacterium tuberculosis in complex with vaborbactammonomer43-307
4D6;PO4;GOL;
Assess
Crystal Structure of Post-isomerized Ertapenem Covalent Adduct with TB B-lactamasemonomer43-307
PO4;2RG;
Assess
Crystal Structure of BlaC-E166A covalently bound with Cefuroximemonomer43-307
DXF;
Assess
Crystal Structure of BlaC-E166A covalently bound with Cefamandolemonomer43-307
PO4;XD2;
Assess
Crystal Structure of BlaC-E166A covalently bound with 6-aminopenicillianmonomer43-307
XD1;PO4;
Assess
Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 2secmonomer43-307
9F2;
Assess
BlaC E166A Faropenem Acyl-Intermediate Complexmonomer43-307
PO4;
Assess
Inhibitor resistant (R220A) substitution in the Mycobacterium tuberculosis beta-lactamasemonomer43-307
PO4;
Assess
Crystal structure of BlaC from Mycobacterium tuberculosismonomer43-307
ACT;GOL;PGE;
Assess
Crystal Structure of BlaC covalently bound with Doripenemmonomer43-307
PO4;DRW;
Assess
BlaC E166A Cefotaxime Acyl-Intermediate Complexmonomer43-307
PO4;
Assess
Crystal Structure of the inhibitor NXL104 Covalent Adduct with TB B-lactamasemonomer43-307
PO4;NXL;
Assess
Beta-lactamase mixed with Ceftriaxone, 5msmonomer43-307
PO4;
Assess
Beta-Lactamase, unmixed shards crystal formmonomer43-307
PO4;
Assess
BlaC E166A CDC-1 Acyl-Intermediatemonomer43-307
PO4;
Assess
Beta-lactamase mixed with Ceftriaxone, 10msmonomer43-307
PO4;
Assess
Beta-lactamase mixed with Ceftriaxone, 50msmonomer43-307
PO4;9F2;
Assess
Beta-lactamase mixed with Sulbactam, 60msmonomer43-307
0RN;PO4;
Assess
Beta-lactamase, mixed with Ceftriaxone, 30ms time point, Shards crystal formmonomer43-307
PO4;9F2;
Assess
BlaC E166A CDC-OMe Acyl-Intermediate Complexmonomer43-307
CD8;
Assess
Crystal Structure of BlaC-E166A covalently bound with Nafcillinmonomer43-307
NFF;
Assess
Beta-lactamase, Unmixedmonomer43-307
PO4;
Assess
BlaC Amoxicillin Acyl-Intermediate Complexmonomer43-307
PO4;
Assess
Crystal structure of BlaC from Mycobacterium tuberculosis bound to phosphatemonomer44-307
PO4;ACT;
Assess
M.tuberculosis betalactamase complexed with inhibitor EC19monomer45-307
PO4;3Y6;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3zhh.1.Amonomer0.9442-307
100.00
Assess